Support comprehensive treatment for pain and substance use disorders
Heading
The AMA urges all health insurance companies and other payers to remove administrative and other barriers to patient care.
Share Your Story
The AMA wants to hear directly from physicians how they are responding to the nation’s opioid epidemic. By sharing your story, you will help inform AMA advocacy in our work on behalf of physicians and patients.
Heading
AMA Education Hub: Opioid and Pain Management: Guidelines, Research and Treatments
Fulfill your state-mandated CME credits while enhancing your knowledge of opioid and non-opioid pain management, safe opioid prescribing and substance use treatment. Learn now.
CME 44.25 Total Credits
Opioid Overdose Prevention Toolkit (En Español)
Substance Abuse and Mental Health Services Administration (SAMHSA)
Finding Quality Treatment for Substance Use Disorders (Spanish Version)
Buscar Tratamiento De Calidad Para Trastornos De Uso De Sustancias
Substance Use, Misuse, and Use Disorders During and Following Pregnancy, with an Emphasis on Opioids
Given the complex needs of pregnant and postpartum women and their children, and the number of systems they encounter during critically important periods in their lives, ASAM provides policy recommendations on substance use, misuse, and SUDs during and following pregnancy.
Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System
JAMA Psychiatry
Public Policy Statement on the Regulation of Office-Based Opioid Treatment
Learn More
Why It’s Inappropriate Not to Treat Incarcerated Patients with Opioid Agonist Therapy
AMA Journal of Ethics. September 2017, Volume 19, Number 9: 922-930.
Sarah E. Wakeman, MD
A Primer on Antagonist-Based Treatment of Opioid Use Disorders in the Office Setting
Learn More
Providers’ Clinical Support System For Medication Assisted Treatment
PCSS-MAT is comprehensive electronic repository of training materials and educational resources to support evidence-based treatment of opioid use disorder, including courses satisfying the DATA-2000 waiver.
DATA 2000-Qualifying Buprenorphine Training
Access 8 hrs of training required for a DEA waiver to prescribe buprenorphine in-office to patients with a substance use disorder.